Comparative Effectiveness Research at the FDA: Taking the “Person” out of Personalized Medicine?

DSpace/Manakin Repository

Comparative Effectiveness Research at the FDA: Taking the “Person” out of Personalized Medicine?

Citable link to this page

. . . . . .

Title: Comparative Effectiveness Research at the FDA: Taking the “Person” out of Personalized Medicine?
Author: Jeans, Megan
Citation: Megan Jeans, Comparative Effectiveness Research at the FDA: Taking the “Person” out of Personalized Medicine? (April 2010).
Full Text & Related Files:
Abstract: of federal funds to comparative effectiveness research (CER), a government project aimed at enhancing efficiency in federal spending by assessing the relative effectiveness of available treatment options across populations. A great deal of literature attempts to predict the likely impact of CER, which is intended to study effectiveness among populations or subgroups, and PM, which focuses on effectiveness in the individual. The general consensus is that the impact will be a positive one, with both strategies mutually enhancing the quality of medical treatment for each individual. Few have expounded upon the effects of CER on PM at the FDA in particular, however. This paper explores some of the ways in which CER may interact with the FDA’s stated goal of furthering PM. It concludes that in spite of certain practical limitations on the symbiotic coexistence of PM and CER, CER is unlikely to obstruct the FDA’s pursuance of PM.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8822188

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters